Compare McDonald's Corp (MCD) vs Pfizer Inc (PFE) Price & Performance

McDonald's (MCD) trades at $267.71, down 2.1% on the day, amid a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.83, beating expectations, with revenue growth to $26.89 billion in 2025 and a net income margin of 31.62%. Recent news highlights the 'McDonald's NEXT' strategy focusing on automation and menu innovation to boost competitiveness.

The outlook is mixed: analyst consensus is bullish with a $329 price target, but technicals indicate near-term pressure. Key risks include inflation impacting franchisee margins and high long-term debt of $38.42 billion. The stock offers a dividend yield supported by stable cash flows, presenting a value opportunity if execution risks are managed.

Pfizer (PFE) trades at $25.05, down 0.36% on the day, with a mixed technical picture showing bullish overall signals but bearish moving averages. The company maintains strong profitability with 73.51% gross margins and has beaten earnings estimates for three consecutive quarters. Recent news highlights Pfizer's focus on obesity and oncology pipeline development as key growth drivers for 2026.

The stock presents a value opportunity with a P/E of 19.12 below industry averages, supported by consistent dividend payments. However, patent cliff concerns and revenue normalization post-COVID remain headwinds. Analyst consensus leans toward Hold with a $28.25 price target, suggesting modest upside potential from current levels.